Recruiting PHASE1 INTERVENTIONAL 7-arm NCT05176483

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors (STELLAR-002)

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors

Sponsor: Exelixis

Conditions Clear Cell Renal Cell Carcinoma (ccRCC) Colorectal Cancer (CRC) Head and Neck Squamous Cell Carcinoma (HNSCC) Hepatocellular Carcinoma (HCC) Metastatic Castration-Resistant Prostate Cancer (mCRPC) Non-Clear Cell Renal Cell Carcinoma (nccRCC) Non-small Cell Lung Cancer (NSCLC) Renal Cell Carcinoma (RCC) Solid Tumor Urothelial Carcinoma (UC)

Interventions Ipilimumab Nivolumab Nivolumab + Relatlimab Zanzalintinib

Updated 23 times since 2022 Last updated: Mar 10, 2026 Started: Dec 14, 2021 Primary completion: Jun 28, 2030 Completion: Jun 28, 2030

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Clear Cell Renal Cell Carcinoma (ccRCC) and Colorectal Cancer (CRC), this trial is actively recruiting participants. The trial is conducted by Exelixis and has accumulated 23 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

23 versions recorded

Mar 2026 — Present [monthly]

Recruiting PHASE1
Feb 2026 — Mar 2026 [monthly]

Recruiting PHASE1

Status: Active Not Recruiting → Recruiting
Sep 2025 — Feb 2026 [monthly]

Active Not Recruiting PHASE1
May 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Nov 2024 — May 2025 [monthly]

Recruiting PHASE1

▶ Show 18 earlier versions

Sep 2024 — Nov 2024 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
May 2024 — Jul 2024 [monthly]

Recruiting PHASE1
Apr 2024 — May 2024 [monthly]

Recruiting PHASE1
Mar 2024 — Apr 2024 [monthly]

Recruiting PHASE1
Feb 2024 — Mar 2024 [monthly]

Recruiting PHASE1
Nov 2023 — Feb 2024 [monthly]

Recruiting PHASE1
Oct 2023 — Nov 2023 [monthly]

Recruiting PHASE1
Sep 2023 — Oct 2023 [monthly]

Recruiting PHASE1
Aug 2023 — Sep 2023 [monthly]

Recruiting PHASE1
Jul 2023 — Aug 2023 [monthly]

Recruiting PHASE1
Jun 2023 — Jul 2023 [monthly]

Recruiting PHASE1
Apr 2023 — Jun 2023 [monthly]

Recruiting PHASE1
Feb 2023 — Apr 2023 [monthly]

Recruiting PHASE1
Sep 2022 — Feb 2023 [monthly]

Recruiting PHASE1
Apr 2022 — Sep 2022 [monthly]

Recruiting PHASE1
Feb 2022 — Apr 2022 [monthly]

Recruiting PHASE1
Jan 2022 — Feb 2022 [monthly]

Recruiting PHASE1

First recorded

Dec 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Exelixis

Data source: Exelixis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albury, Australia , Ancona, Italy , Anderlecht, Belgium , Austin, United States , Badajoz, Spain , Baltimore, United States , Barcelona, Spain , Beersheba, Israel , Besançon, France , Birtinya, Australia and 97 more locations